Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid receptor in brain cells, with the stimulation of this receptor activating multiple gene response elements that promote transcription of anti-inflammatories, antioxidants and efflux channels that remove excess fluid and debris. To put it simply, PRV-002 is intended to reduce swelling, oxidative stress and inflammation, and restore proper blood flow, effects that often arise from mechanical injury to the brain,” reads a recent article that contains excerpts from Odyssey’s white paper. “It’s time to find a treatment for concussion that expedites the return to work, play, school, and military duty; a treatment that can reduce the likelihood of long-term disease. Better helmets and rule changes can assist but will not prevent concussion. However, if the Odyssey drug candidate can reduce the pathological cascade of molecular events that occur in the acute phase of the injury, a substantial improvement in patient outcomes can be achieved in athletic and military settings as well as other commonplace occurrences for concussion.”
To view the full article, visit https://ibn.fm/DAMv4
About Odyssey Health Inc.
Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information about the company, visit www.OdysseyHealthInc.com.
NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
